drugset / Trial / NCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Timeline
- Start
- 2024-12-16
- Primary completion
- 2026-11-15
- Completion
- 2028-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLN-254 | Unknown | — | Oral |